ArticleBlood2009
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 73 citations in OpenAlex.
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.Signal transduction and targeted therapy · 2024Review
- Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules.Antibodies (Basel, Switzerland) · 2021Article
- Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.International journal of molecular sciences · 2021Review
- Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target.Cancer science · 2019Article
- Bispecific antibodies: design, therapy, perspectives.Drug design, development and therapy · 2018Review
- Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.mAbs · 2017Article
- Article
- Target Therapy in Hematological Malignances: New Monoclonal Antibodies.International scholarly research notices · 2014Review
- Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.PloS one · 2014Article
- Fc-fusion proteins: new developments and future perspectives.EMBO molecular medicine · 2012Review
- Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates.Biomacromolecules · 2012Article
- Immunotherapy for B-cell lymphoma: current status and prospective advances.Frontiers in immunology · 2012Article
- Article
- Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines.PloS one · 2012Article
- Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.Blood · 2011Article
- The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.Cancer immunology, immunotherapy : CII · 2011Article
- Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.Journal of the American Chemical Society · 2010Article
- Article
- Targeted treatment and new agents in diffuse large B cell lymphoma.International journal of hematology · 2010Review
- Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.Seminars in nuclear medicine · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The dock and lock (DNL) method is a new technology for generating multivalent antibodies. Here, we report in vitro and in vivo characterizations of 20-22 and 22-20, a pair of humanized hexavalent anti-CD20/22 bispecific antibodies (bsAbs) derived from veltuzumab (v-mab) and epratuzumab (e-mab). The 22-20 was made by site-specific conjugation of e-mab to 4 Fabs of v-mab; 20-22 is of the opposite configuration, composing v-mab and 4 Fabs of e-mab. Each bsAb translocates both CD22 and CD20 into lipid rafts, induces apoptosis and growth inhibition without second-antibody crosslinking, and is significantly more potent in killing lymphoma cells in vitro than their parental antibodies. Although both bsAbs triggered antibody-dependent cellular toxicity, neither displayed complement-dependent cytotoxicity. Intriguingly, 22-20 and 20-22 killed human lymphoma cells in preference to normal B cells ex vivo, whereas the parental v-mab depleted malignant and normal B cells equally. In vivo studies in Daudi tumors revealed 20-22, despite having a shorter serum half-life, had antitumor efficacy comparable with equimolar v-mab; 22-20 was less potent than 20-22 but more effective than e-mab and control bsAbs. These results indicate multiple advantages of hexavalent anti-CD20/22 bsAbs over the individual parental antibodies and suggest that these may represent a new class of cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.